TI
NRIX icon

Trexquant Investment’s Nurix Therapeutics NRIX Stock Holding History

Trexquant Investment’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.25M Buy
209,694
+132,335
+171% +$2.19M 0.02% 824
2025
Q4 		$1.47M Buy
77,359
+62,459
+419% +$897K 0.01% 1078
2025
Q3 		$138K Sell
14,900
-36,633
-71% -$380K ﹤0.01% 1526
2025
Q2 		$587K Buy
+51,533
New +$557K 0.01% 1222
2025
Q1 		– Sell
-22,527
Closed -$424K – 1772
2024
Q4 		$424K Sell
22,527
-136,734
-86% -$3.13M ﹤0.01% 1324
2024
Q3 		$3.58M Sell
159,261
-79,321
-33% -$1.8M 0.05% 608
2024
Q2 		$4.98M Buy
238,582
+25,703
+12% +$400K 0.08% 405
2024
Q1 		$3.13M Buy
212,879
+53,561
+34% +$576K 0.06% 476
2023
Q4 		$1.64M Buy
159,318
+71,252
+81% +$488K 0.04% 622
2023
Q3 		$692K Buy
88,066
+32,212
+58% +$294K 0.02% 889
2023
Q2 		$558K Buy
55,854
+21,107
+61% +$215K 0.01% 963
2023
Q1 		$309K Buy
34,747
+7,697
+28% +$80.2K 0.01% 1188
2022
Q4 		$297K Buy
27,050
+2,064
+8% +$24.9K 0.01% 1110
2022
Q3 		$326K Buy
24,986
+14,636
+141% +$232K 0.01% 992
2022
Q2 		$131K Sell
10,350
-33,978
-77% -$385K 0.01% 1417
2022
Q1 		$621K Buy
44,328
+24,696
+126% +$438K 0.03% 670
2021
Q4 		$568K Buy
+19,632
New +$595K 0.04% 581
2021
Q2 		– Sell
-12,337
Closed -$384K – 1370
2021
Q1 		$384K Buy
+12,337
New +$467K 0.04% 632

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Trexquant Investment's NRIX Position: Q1 2026 in Review

Trexquant Investment increased its Nurix Therapeutics (NRIX) stake by 171% in Q1 2026, buying an estimated $2.19M and bringing the position to 209,694 shares worth $3.25M. The position accounts for 0.02% of the portfolio, ranked #824.

Trexquant Investment first reported a position in NRIX in Q1 2021 and has held it in 18 quarters since. The position peaked at $4.98M in Q2 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Trexquant Investment held 209,694 shares of Nurix Therapeutics worth $3.25M as of Q1 2026.
  • Trexquant Investment bought 132,335 Nurix Therapeutics shares in Q1 2026, an estimated $2.19M.
  • Nurix Therapeutics made up 0.02% of Trexquant Investment's portfolio in Q1 2026, its #824 holding.
  • Trexquant Investment first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • Trexquant Investment's Nurix Therapeutics position peaked at $4.98M in Q2 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.